Investment Rating - The investment rating for the company is "Outperform" (Maintain) [3] Core Insights - The company is set to officially launch the Phase IIc clinical trial for its self-developed recombinant human thymosin β4 (NL005) for the treatment of acute myocardial infarction (AMI) following successful communication with the CDE [4][5] - The company anticipates revenue growth from 0.89 billion yuan in 2025 to 6.11 billion yuan in 2027, with net profits projected to shift from a loss of 440 million yuan in 2025 to a profit of 730 million yuan in 2027 [4][7] - The company has established a significant partnership with a well-known domestic ophthalmology company to promote the localization of its balanced salt solution, enhancing its market presence in the ophthalmic medical sector [5] Financial Summary - Revenue projections for 2025-2027 are 0.89 billion yuan, 2.71 billion yuan, and 6.11 billion yuan respectively, with corresponding net profits of -440 million yuan, -20 million yuan, and 730 million yuan [4][7] - The company’s gross margin is expected to improve from 55.8% in 2025 to 71.5% in 2027, while the net margin is projected to turn positive by 2027 [7][10] - The price-to-sales (P/S) ratio is forecasted to decrease from 78.8 in 2025 to 11.5 in 2027, indicating a potential increase in valuation as revenues grow [4][7]

市公司 时时彩公司书 | 市场数据: | 2025 年 12 月 02 日 | | --- | --- | | 收盘价（元） | 24.45 | | 一年内最高/最低（元） | 32.49/11.05 | | 市净率 | 22.8 | | 股息率%（分红/股价） | | 2025年09月30日 其研教程· 每股净资产 (元) 1.07 | 资产负债率% | 24.41 | | --- | --- | | 总股本/流通 A 股 (百万) | 274/180 | | 流通 B 股/H 股 (百万) | -/- | 年内股价与大盘对比走势： 相关研究 证券分析师 刘靖 A0230512070005 liujinq@swsresearch.com 王雨晴 A0230522010003 wangyq@swsresearch.com 題首德 (920047) — NL005Ⅱc 期临床试验启动在即，增添成长动能 事件: 近日，公司官网发布新闻，由公司自主研发的治疗用生物制品 1 类新药重组人胸腺素β4（代 ● 号 NL005）用于治疗急性心肌梗死（AMI）IIc 期临床研究方案完成与 CDE 的临床试验前沟 通会,公司将 ...

Investment Rating - The report maintains an "Outperform" rating for the company [7] Core Insights - The company has completed the clinical trial communication for its self-developed drug NL005, aimed at treating acute myocardial infarction (AMI), and will officially start the Phase IIc clinical trial [4] - The domestic AMI mortality rate is on the rise, with approximately 50% of AMI patients experiencing myocardial reperfusion injury (MIRI) after treatment [7] - NL005 is expected to start Phase IIc clinical trials in the first half of 2026, with previous studies showing its effectiveness in reducing myocardial infarction area in animal models [7] - The report estimates a peak revenue of approximately 5.5 billion yuan for the product by 2034, applying a 3x price-to-sales (PS) ratio for valuation, leading to a reasonable market value of about 14.9 billion yuan [7] Financial Data and Profit Forecast - Total revenue projections for 2025E are 700 million yuan, with a year-on-year growth rate of -3.0% [6] - The net profit attributable to the parent company is forecasted to be -500 million yuan for 2025E [6] - The gross profit margin is expected to be 49.6% in 2025E, increasing to 71.5% by 2027E [6]

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company reported a stable revenue of 0.37 billion yuan for H1 2025, reflecting a year-on-year growth of 1.5%, with a net loss attributable to shareholders of 0.20 billion yuan [4][7] - The review progress of Sedomin injection is on track, with expectations for commercialization by the end of 2025, although approval may be delayed to H1 2026 due to the innovative nature of the drug [7] - The company is actively preparing for the commercialization of Sedomin injection, including establishing a sales subsidiary and developing a patient support system [7] Financial Data and Profit Forecast - Total revenue projections for the company are as follows: - 2024: 72 million yuan - 2025 H1: 37 million yuan - 2025E: 70 million yuan - 2026E: 173 million yuan - 2027E: 375 million yuan - The expected net profit for 2025E is -0.50 billion yuan, with a projected increase in revenue driven by the launch of Sedomin injection [6][9] - The gross margin is expected to be 49.6% in 2025E, increasing to 71.5% by 2027E [6]